Drug Search Results
More Filters [+]

NP-016

Alternative Names: np-016, np016, np 016
Latest Update: 2017-07-02
Latest Update Note: Clinical Trial Update

Product Description

vaccinia immune globulin can reduce corneal scarring that is sometimes associated with serious vaccinia complications and can impair vision

Mechanisms of Action: PPAR-a Agonist

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Eye Institute (NEI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NP-016

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Vaccinia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

VIG31

P2

Completed

Vaccinia

None

Recent News Events

Date

Type

Title